Eisenmenger syndrome blue book article Flashcards

1
Q

What’s eisenmenger syndrome?

A

a severe phenotype of pulmonary HTN resulting in R) to L) flow through an intracardiac or aorto-pulmonary shunt, usually from congenital cardiac disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What proportion of patients with congenital heart disease survive into adulthood?

A

> 85%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

While most children with CHD do not develop pulm HTN due to advances in diagnostic & surgical procedures, who may some surviving into adulthood still develop PAH?

A

ineffective pulmonary artery banding or residual shunts, rare in high income countries (increased rates of detection & Rx of abnormal circulatory communications)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When eisenmenger syndrome develops, is repair of the underlying defect indicated?

A

No- largely contraindicated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What WHO class of pregnancy would eisenmenger syndrome fall into? maternal mortality?

A

IV- pregnancy contraindicated (as it’s pulmonary HTN)- high risk maternal mortality & severe morbidity. If pregnancy occurs termination should be discussed. If it proceeds, care for as per class III (intensive specialist cardiac & obstetric monitoring required throughout pregnancy, childbirth & postnatally)

30-70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What’s the commonest presentation of congenital cyanotic heart disease in adults & children?

A

eisenmenger syndrome in adults

tetralogy of fallot in children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Within which of the WHO pHTN categories does Eisenmenger syndrome fall?

A

group 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What’s the first step in the pathophysiological cascade leading to eisenmenger syndrome? how does it proceed?

A

systemic-to-pulmonary shunt

increases pulmonary blood flow/pressure, endothelial dysfunction & pulm vascular remodelling, incr PVR, inverted shunt: pulmonary to systemic, cyanosis, eisenmenger

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Roughly what proportion of pts with unrepaired VSD, unrepaired ASD & unrepaired truncus arteriosus are @ risk of developing Eisenmenger syndrome?

A

50%, 10% & almost all

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Is the incidence of pulmonary arterial HTN greater in pts with pre-tricuspid or post-tricuspid shunts?

A

post-tricuspid, as there’s both a combined pressure & volume overload on the RV (as opposed to pre-tricuspid such as ASD or anomalous pulmonary venous return, where it’s predominantly a volume overload); post-tricuspid shunts generally diagnosed in infancy, pre-tricuspid shunts in adulthood. Eg. post-tricuspid include VSD, PDA or complex such as AV septal.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which syndrome has particular propensity to develop pulm HTN & Eisenmenger?

A

Down syndrome, although with early screening & Rx this has decreased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are poor prognostic predictors in pts with eisenmenger?

A
age
pre-tricuspid shunt
lower resting SpO2
absence of sinus rhythm
pericardial effusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which factors are not identified to confer prognostic risk in eisenmenger?

A

functional status (NYHA)
RV function (TAPSE on TOE)
lab data
use of pulm arterial vasodilators

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the clinical picture of Eisenmenger syndrome?

A
Multi-system disease
central cyanosis
dyspnoea
fatigue
haemoptysis
syncope
RHF
with progressive functional deterioration over time

Renal dysfunction common: incl pre-renal from low CO & secondary to glomerular abnormalities due to hypoxaemia & hyperuricaemia

Coagulation derangements: plt dysfunction (incr turnover & aggregation)
elevated plasma vWF:Ag
Vit K-dependent factor deficiency
Factor V & vWF deficiency
hypofibrinoginaemia & increased fibrinolysis

Erythrocytosis from chronic hypoxaemia; predisposed to bleeding & thrombosis

Increased risk to calcium bilirubinate gallstones (from incr haem turnover with erythrocytosis) so more predisposed to cholecystitis

clubbing & hypertrophic pulmonary osteoarthropathy from megacaryocytes bypassing the pulmonary vascular bed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Among patients of a comparable functional class, who has better survival? Eisenmenger or idiopathic PAH? why may this be?

A

Eisenmenger
The R)-L) shunt creates a “pressure relief valve” for the RV which, while at the expense of arterial hypoxaemia, sustains CO by reducing pressure load on the RV & increasing LV preload

Also, there’s a degree of reversibility of the incr PVR in Eisenmenger

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Haemodynamic goals for Eisenmenger:

A

maintain balance between SVR & PVR
AVOID sudden drop in SVR: increases R)–> L) shunt, hypoxaemia & worsening cyanosis, may–> CV collapse & death
AVOID sudden incr SVR which increases afterload & reduces ventricular function, may transmit to incr PVR
avoid factors increasing PVR
AVOID arrhythmias: poorly tolerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why are pts with Eisenmenger @ incr risk for sudden cardiac death during strenuous physical activity?

A

reduced capacity to increase pulm blood flow; exercise increases R)–> L) shunt & cyanosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

patExample of post-tricuspid shunts

A

VSD

PDA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Why may pts with PDA be less symptomatic? What does differential cyanosis in these pts mean?

A

carotid chemoreceptors are exposed to higher PaO2 ejected to upper body
Detectable difference in cyanosis- lower SpO2 in LLs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Why may pts with Eisenmenger be @ higher risk of CVA & brain abscess?

A

paradoxical thromboemboli, air emboli or septic emboli

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are some of the cardiovascular complications of Eisenmenger syndrome?

A
Arrhythmias
sudden cardiac death
valvular heart disease
endocarditis
systolic & diastolic RV & LV dysfunction
20
Q

What are some of the respiratory complications of Eisenmenger syndrome?

A

pulmonary arterial thrombus
pulmonary arterial aneurysms & rupture
haemoptysis
veno-venous collaterals & fistula

21
Q

What are some of the gastrointestinal complications of Eisenmenger syndrome?

A

gallstones (calcium bilirubinate, incr turnover of haem with erythrocytosis)
hyperbilirubinaemia

22
Q

What are some of the haematological complications of Eisenmenger syndrome?

A

erythrocytosis
hyperviscosity syndrome (headaches, dizziness, mental fatigue, syncope, tinnitus, diplopia, blurred vision, amaurosis, paraesthesia, restless legs)
thrombosis
thrombocytopenia (plt dysfunction through consumption & fragmentation)
Fe deficiency
factor V, fibrinogen, vWF & vit K dependent factor deficiencies
hyperfibrinolysis, incr vWF:Ag
incr bleeding risk

23
Q

What are some of the renal complications of Eisenmenger syndrome?

A

hyperuricaemia
gout
renal failure (eg. pre-renal from low CO state & secondary to glomerular abnormalities due to hypoxaemia & hyperuricaemia)

24
Q

What are some of the neurological complications of Eisenmenger syndrome?

A

stroke, TIA

brain abscess

25
Q

What are some of the endocrine complications of Eisenmenger syndrome?

A

neuroendocrine tumours, phaeochromocytoma, gangliomas & neuroblastoma

26
Q

Historically, did digitalis, diuretics, anti-arrhythmics or anticoagulants significantly modify survival or risk of deterioration in eisenmenger’s?

A

No

27
Q

What’s definitive treatment for Eisenmenger’s?

A

Closure of the shunt & lung transplantation or combined heart-lung transplantation

Typically, closure of the R)-L) communication has been contraindicated due to high mortality & poor outcome but when the pulmonary vascular remodelling changes are responsive to Rx, “treat & repair” strategy has been reported

28
Q

What targeted therapies are now offered for Eisenmenger’s?

A
Those targeting pulmonary vasoactive disease likely to be helpful, since most pts with Eisenmenger's retain some degree of pulmonary reactivity:
endothelin antagonists
inhaled prostacyclin & nitric oxide
phosphodiesterase inhibitors
CCBs
29
Q

What’s the overall management of Eisenmenger syndrome?

A

Congenital cardiology specialist along with multi-D congenital cardiology clinic including psychological support

Oxygen controversial- doesn’t improve survival- variable vasodilator response- only use if it produces consistent incr arterial O2 saturation & improved clinical well-being. Care with dehydration of respiratory passages, haemoptysis (pulm haemorrhage).
HFNO often used in hospital
Humidification of any ventilatory system important for secretion clearance & reducing risk of post-op resp failure

Target pharmacotherapies for pulmonary vasoactive disease (which retain some degree of pulmonary vasoreactivity Eisenmenger's) which promote IMPROVEMENTS IN EXERCISE CAPACITY, FUNCTIONAL CLASS, HAEMODYNAMICS, QoL & sometimes SURVIVAL:
Endothelin receptor antagonists (bosentan, ambrisentan selective for ET-A)
prostacyclin (epoprostenol, selexipag= novel prostacyclin analogue)
Phosphodiesterase inhibitors (sildefanil= PDE-5 inhibitor)

Vaccines to prevent influenza & pneumococcal pneumonia & COVID-19

diuretics if show signs of RHF with fluid retention

Definitive Rx= closure of the R)-L) shunt & lung or heart-lung transplant.

30
Q

When does hyperviscosity syndrome generally occur? Should routine phlebotomy be performed for Eisenmenger’s? Why?

A

Hb >200g/L & Hct >65%

Should not perform chronic phlebotomy in asymptomatic or mildly symptomatic Eisenmenger pts as it may cause Fe deficiency (to which pts are susceptible anyway in the setting of erythrocytosis) & this is a problem as the microcytic erythrocyte is less deformable & prone to causing hyperviscosity cf normocytic erythrocytes @ a comparable Hct.

Only perform isovolaemic replacement if mod-severe symptoms of hyperviscosity (headaches, dizziness, tinnitus, diplopia, blurred vision, amaurosis, mental fatigue/poor concentration, syncope, paraesthesia, myalgia, restless legs); phlebotomy of 250-500mL blood over an hour whilst infuse 750-1000mL of saline.

Consider preoperative phlebotomy for autologous blood donation if the Hct is >65%.

31
Q

What’s the susceptibility to severe COVID-19 infection in Eisenmenger’s?

A

risk for most pts with congenital heart disease commensurate with general population & risk factors derived from the general population (age, overweight, DM, renal insufficiency, multiple comorbidities)
however Eisenmenger= a subgroup at incr risk for complicated disease

32
Q

Anaesthetic considerations for Eisenmenger syndrome?

A

High risk: peri-operative mortality 4-18%
Multi-D approach to pt Ax- involve pt’s congenital heart disease Cardiologist & others experienced in these cases
Multi-D discussion re: necessity of procedure (limit to essential procedures, perform only at specialised centres by experienced clinicians, daylight hours)
careful discussion re: risks of anaes, surgery & postop recovery in the gaining of informed consent

PREOP:
History/Ix gathered: type of defect, complications related to prior procedures
shunt direction
chambers affected
echo (mandated annually): ventricular function, pulmonary artery pressures
cardiac MRI
Exam:
Resting SpO2

Preparation:
preop G&H (may have antibodies) & obtain cross-matched blood as needed
Particular caution re: accuracy of blood tests in presence of erythrocytosis

INTRAOP:
consider NGT in cases of prolonged withdrawal of pulmonary vasodilators, consider IV route if enteral absorption compromised
antibiotic prophylaxis: unprepared cyanotic defects

Consider intra-op TOE

Haemodynamic principals:
Avoid increased PVR & decreased SVR (which increase R)–> L) shunt)
Consider ketamine, etomidate, dexmed or midaz to minimise CV effects from GA agents (care with remi & dexmed due to risks with hypoT & Brady in pulm HTN)
Titrate phenylephrine/metaraminol to maintain SVR (care as risks incr PVR)
Aggressively avoid blood loss/coagulopathy; bleeding may precipitate arterial hypoT which increases R)–> L) shunt, reduces DO2 & perfusion pressure to the RV, compounded if faced with incr O2 demand to the RV from PAH worsened by hypoxaemia & academia.
CAN do gently titrated neuraxial (epi top-up or spinal catheter), cognisant of avoiding preload & afterload losses

Ventilation: avoid high Pit or atelectasis (all risk raising PVR)

Be particularly vigilant to risk of air embolus

POSTOP:
low threshold for ICU monitoring
ensure adequate analgesia (limit SNS) care with analgesics which may precipitate hypoventilation or afterload reduction
VTE prophylaxis (mech devices, compression stockings, early ambulation)
care re: postop thrombotic & bleeding diatheses
attention to fluid balance, sepsis or inflammatory responses (particularly to avoid postural hypoT & secondary incr R)->L) shunt)
cardiology input re: pulm vasodilators if prolonged interruption eg. ventilated or postop ileum, consider IV agents (eg. sildefanil) or inhaled nitric oxide
SpO2 & BP targets postop should be the pts usual resting values

33
Q

Why is pneumoperitoneum particularly problematic for Eisenmenger syndrome?

A

factors that increase PVR: hypercapnia impaired FRC/lung volumes (pneumoperitoneum, potential for head down), SNS stimulation

risk of impaired preload (reduced venous return) which puts the R) heart at risk

Risk of increased afterload- while main focus is to avoid reduced SVR which increases R)–> L) shunting, care that not excessive afterload

risk of gas embolisation

34
Q

What are the issues with spinal catheter?

A

FDA has withdrawn approval for small-bore catheters for continuous spinal anaesthesia due to cauda equina syndrome (which may have been due to hyperbaric 5% lignocaine)
larger epidural catheters= unacceptable risk of PDPH
catheter-over-needle system eg. Braun spinocath= alternative

35
Q

What are some of the concerns with invasive lines in Eisenmenger pts?

A
risk of endocarditis
paradoxical emboli
vascular damage
arrhythmias
with PA catheters: PA rupture

balance benefits of monitoring with risks of insertion

36
Q

how may thermodilution determinants of CO be misleading in Eisenmengers?

A

the type & degree of shunt

37
Q

What are some particular considerations with lab tests in erythrocytosis?

A

If Hct >55%, the citrate fraction in coag tubes is excessive for the plasma & coagulation studies will be inaccurate; the amount of anticoagulant must be adjusted to an acceptable ratio

blood glucose measurement can be falsely lowered by high red cell metabolic activity unless a fluoride tube is used

non-invasive Hb is unreliable in cyanotic heart disease (error in co-oximetry derived Hb increases as O2 sat decreases)

38
Q

How does pregnancy confer particular risk for Eisenmenger? when is the greatest time of risk?

A

Peripheral VD & high placental flow with reduced SVR may exacerbate R)–> L) shunt
excess plasma volume may overload/compromise RV
increased risk thromboembolism
increased metabolic & CO demand with incr HR along with reduced Hct may–> myocardial O2 supply >demand

Biggest risk peripartum: large volume shifts & exhaustion of cardiac reserve

39
Q

Particular obstetric anaesthesia considerations in Eisenmenger?

A

Location: at the very least at tertiary centre controlled induction in-hours with availability of the pts congenital heart disease specialist & cardiac anaesthetist, consider delivery in cardiac theatre for high-risk cases
Multi-D discussion (cards/obs/paeds) re: timing- inductions at early gestation considered if risk of continued pregnancy outweighs risk of prematurity
Consider availability of V-V & V-A ECMO

Neuraxial: may be on uninterrupted anticoagulation necessitating avoidance of neuraxial yet early epidural facilitates primary goals of short labour, avoidance of SNS stimulation, avoid strenuous expulsive efforts (vacuum or forceps delivery)

Avoid uterotonic boluses (oxytocin) as risk sudden SVR reductions- oxytocin best by slow IV infusion

avoid ergometrine (PVR), misoprostol (reduced SVR) & carboprost (pulmonary VC)

40
Q

What’s the recommended delivery mode for obstetric Eisenmenger’s?

A

Vaginal- vacuum or forceps assisted

CS associated with higher risk of death

41
Q

how may V-V ecmo be useful in pregnant eisenmenger pts?

A

Due to reversal of shunt, oxygenated blood is delivered directly to the systemic circulation, maximising foetal oxygenation

42
Q

The R) to L) shunt of eisenmenger leads to what pharmacological alterations?

A

slower inhalational induction esp of relatively insoluble agents
faster IV induction (faster arm-brain circulation time)
lack of pulmonary endothelial extraction which is important in buffering the rate of rise of some drugs (some LAs, opioids such as fentanyl, to a lesser extent prop & this)

43
Q

What’s the pulmonary extraction of lignocaine, prilocaine & bupivacaione?

A

50%, 40%, 12%

44
Q

What’s the pulmonary extraction of fentanyl? alfentanil? morphine?

A

75%; significant
10%
4-7%

45
Q

What’s the pulmonary extraction of propofol? this?

A

28%
14%

this combined with low arm-brain circulation time= take care with prop administration if significant R)-L) shunt

46
Q

What are the most common causes of death in Eisenmengers nowadays?

A

HF–> infection–> SCD–> thrombosis–> haemorrhage

47
Q

What’s the best contraception for Eisenmonger’s?

A

no consensus
hormone-based contraception is pro-thrombotic
progesterone containing contraceptives may interact with endothelin receptor antagonists but are the preferred methods

48
Q

Is MAC safer than GA in Eisenmenger?

A

Not necessarily; in one series, 67% of O2 desalts occurred during MAC